Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, announced it has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognized for its innovative approach to addressing cancer drug resistance. The award highlights the company's strategy centered on resistance-modulating treatments, including its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.
This recognition is significant because it validates Kairos Pharma's focus on one of the most pressing challenges in oncology: drug resistance. Many patients initially respond to cancer therapies but eventually relapse as tumors evolve mechanisms to evade treatment. By targeting CD105, a protein identified as a key driver of resistance and disease relapse, ENV-105 aims to reverse drug resistance and restore the efficacy of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs.
The Pinnacle Award places Kairos Pharma among leading healthcare innovators, potentially attracting attention from investors and collaborators interested in advancing resistance-modulating therapies. As the company progresses its clinical trials, positive results could transform treatment paradigms, offering patients more durable responses and improved outcomes. The award also underscores the importance of structural biology in oncology therapeutics, a field in which Kairos Pharma specializes.
For more information about the award and Kairos Pharma's pipeline, refer to the full press release at https://ibn.fm/ghPJC. Updates on the company's progress are available in its newsroom at https://ibn.fm/KAPA.
